What is Microbiotica?
Microbiotica is a pioneering entity in the development of microbiome-based therapeutics, biomarkers, and targets. Leveraging a proprietary platform that includes a leading microbiome Reference Genome Database, Culture Collection, and advanced AI tools, the company excels at strain-level microbiome analysis linked to patient phenotypes. Spun out from the Sanger Institute in 2016 and based at Chesterford Research Park near Cambridge, UK, Microbiotica focuses its therapeutic efforts on immuno-oncology and Inflammatory Bowel Disease (IBD), supported by substantial clinical and academic collaborations. The company's platform enables the creation of differentiated products derived from high-quality clinical datasets and unique bacterial signatures that influence biology.
How much funding has Microbiotica raised?
Microbiotica has raised a total of $201M across 3 funding rounds:
Multiple Rounds
$201M
Series B (2022): $67M with participation from Flerie Invest and Tencent
Series B (2022): $67M led by Seventure Partners, IP Group, Cambridge Innovation Capital, British Patient Capital, Tencent, and Flerie Invest
Series B (2022): $67M supported by Flerie Invest and Tencent
Key Investors in Microbiotica
British Patient Capital
British Patient Capital, part of the British Business Bank, provides financial support and equity finance to UK businesses, focusing on start-ups and growing companies to drive innovation and expansion.
Cambridge Innovation Capital
Cambridge Innovation Capital is a venture investor backing entrepreneurs in life sciences and deep tech, particularly within the Cambridge ecosystem, offering financial backing and expert guidance.
Seventure Partners
Seventure Partners actively invests in innovative companies within life sciences and digital technologies, focusing on health, nutrition, and sustainable initiatives.
What's next for Microbiotica?
The substantial enterprise-level funding Microbiotica has attracted signals a critical growth phase, likely focused on scaling its operations, advancing its pipeline through clinical trials, and potentially expanding its strategic partnerships. This investment will be instrumental in further developing its unique bacterial signatures and AI-driven analysis capabilities. The company's strategic focus on immuno-oncology and IBD, coupled with its robust technological foundation, positions it for significant advancements in the precision medicine space. Future developments will likely involve translating its platform's analytical power into approved therapeutic products and expanding its market reach.
See full Microbiotica company page
